Page last updated: 2024-11-05

ethyl acrylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ethyl acrylate is a colorless liquid with a slightly sweet odor. It is a versatile monomer used in the production of various polymers, including acrylic resins, adhesives, coatings, and elastomers. It is typically synthesized through the reaction of acrylic acid with ethanol in the presence of an acid catalyst. Ethyl acrylate is known to be a skin and eye irritant, and prolonged exposure can cause respiratory problems. However, it is also known for its biocompatibility and has been studied for its potential applications in drug delivery systems and tissue engineering. Ethyl acrylate is extensively studied due to its wide range of applications and its potential to improve existing materials and processes. '

Cross-References

ID SourceID
PubMed CID8821
CHEMBL ID52084
CHEBI ID82327
SCHEMBL ID3180
MeSH IDM0121381

Synonyms (112)

Synonym
ethyl acrylate, inhibited
nci-c50384
ethylakrylat
140-88-5
nsc8263
wln: 2ov1u1
ethyl propenoate
etil acrilato
acrylate d'ethyle
ethyl 2-propenoate
acrylic acid, ethyl ester (inhibited)
nsc-8263
acrylic acid, ethyl ester
ethyl acrylate
etilacrilatului(roumanian)
ethylacrylaat
acrylic acid ethyl ester
2-propenoic acid, ethyl ester
propenoic acid,ethyl ester (ethylacrylate)
inchi=1/c5h8o2/c1-3-5(6)7-4-2/h3h,1,4h2,2h
aethylacrylat
acrylsaeureaethylester
ethyl acrylate (inhibited)
NCGC00091041-01
ethyl acrylate, inhibited [un1917] [flammable liquid]
ai3-15734
fema number 2418
ethyl acrylate (natural)
acrylsaeureaethylester [german]
fema no. 2418
akrylanem etylu [polish]
2-propenoic acid ethyl ester
un1917
etil acrilato [italian]
ethylester kyseliny akrylove [czech]
carboset 511
ethylakrylat [czech]
hsdb 193
ethoxycarbonylethylene
ccris 248
aethylacrylat [german]
acrylate d'ethyle [french]
ethylacrylaat [dutch]
einecs 205-438-8
brn 0773866
rcra waste number u113
etilacrilatului [romanian]
ethyl propenoate, inhibited
nsc 8263
rcra waste no. u113
ethyl acrylate, contains 10-20 ppm mehq as inhibitor, 99%
ethyl acrylate, >=99.5%, stabilized, fg
A0143 ,
CHEMBL52084
chebi:82327 ,
ethyl prop-2-enoate
9003-32-1
AKOS005721113
C19238
ethyl 2e-propenoate
LMFA07010505
we(2:0/3:1(2e))
tox21_202513
NCGC00260062-01
dtxsid4020583 ,
dtxcid00583
cas-140-88-5
BBL011497
2-propenoic acid, 1,1'-((dihydro-5-(2-hydroxyethyl)-2,4,6-trioxo-1,3,5-triazine-1,3(2h,4h)-diyl)di-2,1-ethanediyl) ester
ethyl acrylate stabilized with 10 - 20 ppm mehq
STL146609
ec 205-438-8
unii-71e6178c9t
71e6178c9t ,
akrylanem etylu
4-02-00-01460 (beilstein handbook reference)
ethyl acrylate, inhibited [un1917] [flammable liquid]
ethylester kyseliny akrylove
etilacrilatului
FT-0625767
FT-0621878
ethyl acrylate [fhfi]
ethyl acrylate [inci]
ethyl acrylate [iarc]
ethyl acrylate [mi]
ethyl acrylate [fcc]
ethyl acrylate [hsdb]
SCHEMBL3180
ethyl ester of 2-propenoic acid
ch2=chcooc2h5
F1908-0175
ethyl acrylate, analytical standard
mfcd00009188
ethyl acrylate, purum, >=99.0% (gc)
ethyl acrylate, saj first grade, >=99.0%
ethyl acrylate, stabilized with mehq
ethyl acrylate (stabilized with mehq)
fema 2418
propenoic acid,ethyl ester (ethylacrylate)
J-007427
acrylic acid-ethyl ester
BCP06341
fema-2418
Q343014
35717-06-7
VS-02962
AMY40211
ethyl-d5 acrylate
ethyl acrylate (stabilized with 4-methoxyphenol)
EN300-19964
ethyl acrylate (iarc)
ethyl acrylate 1000 microg/ml in methanol

Research Excerpts

Overview

Ethyl acrylate (EA) is an acrylic monomer used in the manufacture of a variety of polymers and copolymers. EA is a known forestomach carcinogen in both rats and mice.

ExcerptReferenceRelevance
"Ethyl acrylate is an irritant known to affect the upper airways and eyes. "( Clinical Effects, Exhaled Breath Condensate pH and Exhaled Nitric Oxide in Humans After Ethyl Acrylate Exposure.
Beine, A; Berresheim, H; Brüning, T; Bünger, J; Hoffmeyer, F; Jettkant, B; Monsé, C; Sucker, K,
)
1.8
"Ethyl acrylate (EA) is an acrylic monomer used in the manufacture of a variety of polymers and copolymers as components of many commercially important products. "( Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate.
Iatropoulos, MJ; Williams, GM, 2009
)
2.03
"Ethyl acrylate (EA) is a known forestomach carcinogen in both rats and mice. "( Demonstration of a temporal relationship between ethyl acrylate-induced forestomach cell proliferation and carcinogenicity.
Elwell, MR; Ghanayem, BI; Matthews, HB; Sanchez, IM,
)
1.83
"Ethyl acrylate is a monomer used extensively in polymer manufacturing. "( Rates of ethyl acrylate binding to glutathione and protein.
Potter, DW; Tran, TB, 1992
)
2.14

Toxicity

ExcerptReferenceRelevance
" Unmodified PEI is highly toxic at such polymer concentrations."( Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity.
Dehshahri, A; Philipp, A; Wagner, E; Zintchenko, A, 2008
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
"A physiologically based pharmacokinetic and pharmacodynamic model has been developed to describe the absorption, distribution, and metabolism of orally dosed ethyl acrylate."( A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment.
Andersen, ME; Chang-Mateu, MI; Frederick, CB; Potter, DW, 1992
)
0.69

Bioavailability

ExcerptReferenceRelevance
"The aim of the present work was to investigate the in vitro dissolution properties and oral bioavailability of three solid dispersions of nimodipine."( Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion.
Tang, X; Wang, Z; Yang, R; Zhang, Y; Zheng, L; Zheng, X, 2007
)
0.34

Dosage Studied

Gavage dosing of the irritant, ethyl acrylate (EA), has been found to induce hyperplasia in the rat forestomach. There were no signs of toxicity in the glandular stomach or in organs remote from the site of dosing.

ExcerptRelevanceReference
"A physiologically based pharmacokinetic and pharmacodynamic model has been developed to describe the absorption, distribution, and metabolism of orally dosed ethyl acrylate."( A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment.
Andersen, ME; Chang-Mateu, MI; Frederick, CB; Potter, DW, 1992
)
0.69
"Male F344/N rats were dosed with ethyl acrylate (EA) either by daily gavage or in the drinking water for 2 weeks."( The histopathological and biochemical response of the stomach of male F344/N rats following two weeks of oral dosing with ethyl acrylate.
Frantz, JD; Frederick, CB; Hazelton, GA, 1990
)
0.77
"Rats receiving 14 daily gavage doses of 100 or 200 mg/kg ethyl acrylate (EtAc) and killed at varying times following the end of dosing exhibited dose-dependent lesions and recovery from lesions in the forestomach."( Ethyl acrylate-induced gastric toxicity. III. Development and recovery of lesions.
Ghanayem, BI; Maronpot, RR; Matthews, HB, 1986
)
1.96
"Following oral dosing of [2,3-14C]acrylic acid (AA; 4, 40, or 400 mg/kg) and [2,3-14C]ethyl acrylate (EA; 2, 20, or 200 mg/kg), the dosed radioactivity was rapidly excreted, with 50-75% of the dose for both compounds eliminated within 24 hr."( The disposition and metabolism of acrylic acid and ethyl acrylate in male Sprague-Dawley rats.
deBethizy, JD; Frederick, CB; Scribner, HE; Udinsky, JR, 1987
)
0.75
" The excretion of urinary metabolites was studied in rat dosed intraperitoneally with ethyl acrylate and 1-butyl acrylate."( Biotransformation of acrylates. Excretion of mercapturic acids and changes in urinary carboxylic acid profile in rat dosed with ethyl and 1-butyl acrylate.
Linhart, I; Smejkal, J; Vosmanská, M, 1994
)
0.51
"Gavage dosing of the irritant, ethyl acrylate (EA), has been found to induce hyperplasia in the rat forestomach, but no signs of toxicity in the glandular stomach or in organs remote from the site of dosing."( Quantitation of an epithelial S-phase response in the rat forestomach and glandular stomach following gavage dosing with ethyl acrylate.
Frederick, CB; Gillette, DM, 1993
)
0.78
" Based on dose-related increases in skin hyperplasia following dermal exposure to EA, TPGDA, or Lacquer A (applied equimolar for TPGDA concentration), the dosing regimen was selected."( Tripropylene glycol diacrylate but not ethyl acrylate induces skin tumors in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice.
French, JE; Nylander-French, LA,
)
0.4
" Viability of the cells after 2-24-h exposure to the representative monofunctional or multifunctional acrylate or solvent control was used to calculate an index of acute cytotoxicity (50% inhibitory dose; ID50) and to determine the shape of the dose-response curves."( Comparative in vitro cytotoxicity of ethyl acrylate and tripropylene glycol diacrylate to normal human skin and lung cells.
French, JE; Nylander-French, LA, 2000
)
0.58
"Chronic repeated gavage dosing of high concentrations of ethyl acrylate (EA) causes forestomach tumors in rats and mice."( Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans.
Borghoff, S; Chappell, G; Ellis-Hutchings, R; Finch, L; Proctor, DM; Suh, M; Thompson, CM; Wiench, K, 2018
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
enoate esterAn alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency69.84710.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.97110.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1469819Glutathione reactivity of the compound in DMSO and phosphate buffer assessed as second order rate constant for adduct formation2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.
AID174708Gastric cytoprotective activity in male wistar rat1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-cytoprotective activity relationship of simple molecules containing an alpha,beta-unsaturated carbonyl system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (133)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (15.79)18.7374
1990's33 (24.81)18.2507
2000's31 (23.31)29.6817
2010's41 (30.83)24.3611
2020's7 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.12 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index103.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.71%)5.53%
Reviews8 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other131 (93.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]